Litigation Details for Gilead Sciences, Inc. v. Lee (Fed. Cir. 2013)

Gilead Sciences, Inc. v. Lee (Fed. Cir. 2013)

Docket		Date Filed	2013-12-11
Court	Court of Appeals for the Federal Circuit	Date Terminated	2015-02-26
Cause		Assigned To
Jury Demand		Referred To
Patents	8,148,374
Link to Docket	External link to docket

Details for Gilead Sciences, Inc. v. Lee (Fed. Cir. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-12-11				External link to document

Gilead Sciences, Inc. v. Lee, 14-1159: Patent-Term Adjustment Litigation Summary and Analysis

Last updated: September 27, 2026

Gilead Sciences, Inc. v. Lee, No. 14-1159, addressed how the USPTO calculates patent-term adjustment under 35 U.S.C. § 154(b) when agency delay occurs during the same period as the statutory three-year examination delay. The Federal Circuit affirmed the USPTO’s “overlap” methodology and held that overlapping delay periods cannot be counted twice. The decision limited the ability of patentees to extend patent terms through cumulative A-delay and B-delay calculations. (Gilead Scis., Inc. v. Lee, 2015)

What was Gilead Sciences v. Lee about?

The case concerned the calculation of patent-term adjustment, or PTA, for a Gilead patent. PTA compensates patentees for certain USPTO delays that occur during prosecution.

The dispute involved two statutory categories:

• A delay under 35 U.S.C. § 154(b)(1)(A), which covers the USPTO’s failure to meet specified examination and prosecution deadlines.
• B delay under 35 U.S.C. § 154(b)(1)(B), which generally applies when the USPTO does not issue a patent within three years after the application’s filing date, subject to applicant-caused delays and other statutory exclusions.

Gilead argued that the USPTO improperly reduced its PTA by treating certain A-delay and B-delay days as overlapping. The company contended that the two categories represented distinct forms of agency delay and should be added together unless they arose from the same underlying event.

The Federal Circuit rejected that interpretation. It held that overlapping A-delay and B-delay periods must be excluded from the combined PTA calculation, even when the delays arise from different statutory provisions or different agency actions. (Gilead Scis., Inc. v. Lee, 2015)

What did the Federal Circuit decide in Gilead v. Lee?

The Federal Circuit affirmed the USPTO’s method of calculating PTA and held that the agency’s interpretation of “overlap” under § 154(b)(2)(A) was reasonable.

The court’s core conclusion was that a single calendar day cannot be counted twice as patent-term adjustment. If A delay and B delay occur on the same day, that day is an overlapping delay day and must be counted only once.

The court rejected Gilead’s argument that “overlap” requires the two delays to be caused by the same event. The statutory inquiry focuses on whether the delay periods occur during the same time, not whether the USPTO’s failures have identical causes.

Case metadata

Item	Detail
Case	Gilead Sciences, Inc. v. Lee
Federal Circuit docket	No. 14-1159
Court	U.S. Court of Appeals for the Federal Circuit
Decision date	February 26, 2015
Citation	778 F.3d 1341
Statute at issue	35 U.S.C. § 154(b)
Agency defendant	Director of the USPTO, then Michelle K. Lee
Disposition	Affirmed
Primary issue	Calculation of overlapping PTA under A-delay and B-delay provisions
Broader impact	Restricted cumulative counting of overlapping USPTO delay

The Federal Circuit’s ruling became a leading authority on PTA calculations. It also influenced subsequent litigation concerning the scope of B delay, applicant-caused delay, and the interaction of the various PTA categories.

How does patent-term adjustment work under 35 U.S.C. § 154(b)?

Patent term generally runs for 20 years from the earliest effective nonprovisional U.S. filing date. PTA can extend that term when the USPTO fails to meet statutory processing deadlines.

A delay

A delay compensates for specific USPTO failures, including delays in:

• Issuing a first office action within the statutory period.
• Responding to a reply within the prescribed period.
• Acting on an application after a successful appeal.
• Issuing a patent after the issue fee has been paid.
• Meeting other examination-related deadlines established by statute or regulation.

A delay is usually calculated by comparing prescribed agency deadlines with actual USPTO action dates.

B delay

B delay generally applies when a patent does not issue within three years after the application’s filing date. The calculation is subject to exclusions for:

• Applicant-requested delays.
• Continued examination practice.
• Certain appeals.
• Requests for suspension.
• Other applicant-caused prosecution delays.

C delay

C delay applies to delays caused by:

• Appeals.
• Interferences.
• Derivation proceedings.
• Secrecy orders.

The statute requires the USPTO to calculate these categories and then subtract periods of overlap. Gilead v. Lee primarily concerned the meaning of that overlap requirement.

What patent-term calculation rule did Gilead v. Lee establish?

The decision established a calendar-based overlap rule.

When two statutory delay periods cover the same day:

1. The day may be included in the total PTA only once.
2. The fact that the delays arise under different statutory subsections does not permit double counting.
3. The delays need not have the same cause.
4. The USPTO may subtract overlapping days from the aggregate A-plus-B calculation.

This approach prevents a patentee from receiving more than one day of PTA for a single day of USPTO delay.

The ruling addressed an important distinction between delay categories and delay days. A-delay and B-delay categories remain legally distinct, but their accounting is cumulative only to the extent that their covered calendar periods do not overlap.

Why was the overlap issue commercially important?

Patent-term adjustment can affect the timing of generic entry, licensing value, product-line revenue, and patent litigation strategy. Even a modest PTA difference can affect a drug with substantial annual sales.

For a small-molecule product, an additional period of patent protection may:

• Delay an ANDA applicant’s commercial launch.
• Extend the period during which the branded company can enforce patent rights.
• Increase settlement leverage in Paragraph IV litigation.
• Preserve exclusivity for a formulation, method of use, or active-ingredient patent.
• Affect projected revenue and royalty calculations.

Gilead v. Lee made PTA calculations less favorable to patentees that had experienced multiple types of USPTO delay during the same period. The ruling also increased the importance of independently auditing the USPTO’s day-by-day PTA calculation.

Did Gilead v. Lee involve Paragraph IV litigation?

No. Gilead v. Lee was not a Hatch-Waxman infringement case and did not involve an ANDA filer, a Paragraph IV certification, or a generic drug launch.

The dispute was between Gilead and the USPTO over the term of a patent. The case did not determine:

• Whether a generic product infringed.
• Whether a patent was valid.
• Whether a patent was Orange Book-listed.
• Whether a generic applicant could launch before patent expiration.
• Whether a settlement agreement violated antitrust or Hatch-Waxman rules.

Its relevance to Paragraph IV litigation is indirect. The decision affects the patent expiration date that parties use when assessing generic-launch timing.

What was the litigation status and procedural history?

Gilead sought judicial review of the USPTO’s PTA calculation. The district court upheld the agency’s approach. Gilead appealed to the Federal Circuit.

The Federal Circuit affirmed the district court and the USPTO. The court treated the statutory overlap provision as controlling and found the USPTO’s interpretation reasonable.

Procedural timeline

Date	Event
2014	Gilead appealed the district court judgment to the Federal Circuit
February 26, 2015	Federal Circuit issued its decision
February 2015	Judgment affirmed the USPTO’s overlap calculation
Post-decision	The ruling became controlling Federal Circuit authority on the disputed PTA methodology

The case did not produce a damages award, injunction, generic settlement, or license judgment.

How did Gilead v. Lee affect USPTO patent-term calculations?

The decision reinforced the USPTO’s practice of calculating PTA by identifying the relevant delay periods and removing overlap before determining the final adjustment.

Patent owners must distinguish between:

• The gross number of A-delay days.
• The gross number of B-delay days.
• The gross number of C-delay days.
• Applicant-caused reductions.
• Overlapping days.
• The final PTA shown on the patent certificate.

A patent owner cannot assume that the sum of the individual statutory delay categories equals the final adjustment.

The decision also made prosecution records commercially important. A PTA audit may require review of:

• Filing dates.
• First-action dates.
• Office-action response dates.
• Requests for continued examination.
• Appeal periods.
• Issue-fee payment dates.
• Notices of allowance.
• Applicant-requested extensions.
• USPTO PTA determinations.

Does Gilead v. Lee affect Orange Book patents?

The decision applies to any U.S. patent eligible for PTA, including patents that may be listed in the FDA Orange Book. It does not itself establish an Orange Book listing rule.

A branded pharmaceutical company evaluating Orange Book exposure should treat the PTA date as one component of the patent’s enforceable term. The Orange Book may identify patents covering:

• Active ingredients.
• Drug products.
• Formulations.
• Methods of use.

The Gilead decision affects the expiration date used in that analysis where PTA is available. It does not determine whether a patent is listable under FDA regulations or whether a listing is substantively valid.

What formulation and method-of-use issues are affected?

The decision does not distinguish between compound, formulation, manufacturing, or method-of-use patents. Its rule applies to the PTA calculation for the relevant patent regardless of claim type.

Formulation patents

A formulation patent may protect:

• Dosage form architecture.
• Controlled-release systems.
• Excipients.
• Particle size.
• Stability characteristics.
• Fixed-dose combinations.

If the patent receives PTA, the Gilead overlap rule controls the adjustment.

Method-of-use patents

A method-of-use patent may cover:

• A dosing regimen.
• A treatment population.
• A line of therapy.
• A safety-related administration protocol.
• A disease-specific use.

For an Orange Book-listed method-of-use patent, the PTA expiration date can influence the timing and scope of a generic applicant’s Paragraph IV certification.

Manufacturing patents

Manufacturing patents may protect:

• Synthetic routes.
• Intermediates.
• Purification methods.
• Crystallization processes.
• Polymorph production.
• Pharmaceutical-grade manufacturing controls.

These patents may not always be listed in the Orange Book, but their adjusted term can affect supply-chain freedom to operate and process licensing.

Is Gilead v. Lee relevant to biosimilar patent risk?

Only indirectly.

Gilead v. Lee concerns conventional U.S. patent-term adjustment. Biosimilar disputes generally involve biologic products, the Biologics Price Competition and Innovation Act, patent-information exchanges, and patent litigation under 35 U.S.C. § 271(e)(6) and related provisions.

The ruling does not address:

• FDA biologic exclusivity.
• BPCIA patent dance procedures.
• Reference-product exclusivity.
• Interchangeability.
• Biosimilar substitution.
• Patent-listing obligations for biologics.

For biologics, PTA may still affect individual patents, but the commercial exclusivity analysis also requires separate review of regulatory exclusivity and the biologic patent estate.

Which companies challenged the Gilead patent term?

The litigation was brought by Gilead against the USPTO. No generic manufacturer, biosimilar developer, or competing pharmaceutical company was a named challenger in the reported appeal.

There was no disclosed Paragraph IV settlement, cross-license, co-development agreement, or commercial litigation resolution between Gilead and a generic company in the case.

How strong was Gilead’s legal position?

Gilead’s argument had a plausible textual basis because the statute separately identifies A delay and B delay. The company argued that separate statutory violations should generate separate adjustments unless the delays were caused by the same event.

The Federal Circuit found the USPTO’s reading stronger because:

• The statute requires subtraction of overlapping periods.
• “Overlap” is naturally read as a temporal concept.
• Double counting the same calendar day would produce more than one day of adjustment for one day of time.
• The agency’s interpretation was consistent with the statutory structure.

The ruling reduced the likelihood that a patentee could obtain cumulative PTA merely by characterizing the same period under multiple delay categories.

What generic-launch risks follow from the decision?

The principal generic-launch risk is an incorrectly estimated patent expiration date.

A generic applicant or branded company should model at least three dates:

Date	Commercial significance
Base 20-year expiration	Term calculated without PTA
USPTO-issued expiration	Term shown after the agency’s PTA calculation
Recalculated litigation date	Expiration date after any successful PTA challenge

The difference can affect:

• Paragraph IV notice timing.
• First-filer exclusivity assumptions.
• Launch-at-risk analysis.
• Settlement economics.
• Damages exposure.
• Revenue forecasts.
• Patent portfolio valuation.

A company relying on an unverified USPTO expiration date may overestimate or underestimate exclusivity.

What is the geographic scope of the ruling?

The decision applies to U.S. patent-term adjustment under 35 U.S.C. § 154(b). It does not control patent-term extensions or prosecution-delay regimes in Europe, Japan, China, Canada, or other jurisdictions.

The ruling has no direct effect on:

• European supplementary protection certificates.
• Japanese patent-term adjustment.
• Canadian patent-term restoration.
• Chinese patent-term compensation.
• Australian pharmaceutical extension provisions.

Multinational pharmaceutical companies must calculate U.S. PTA separately from foreign patent-term mechanisms.

Key Takeaways

• Gilead Sciences, Inc. v. Lee, 778 F.3d 1341 (Fed. Cir. 2015), affirmed the USPTO’s overlapping-delay methodology.
• A-delay and B-delay periods cannot be double counted when they cover the same calendar days.
• The delays do not need to arise from the same agency action to overlap.
• The case was a PTA dispute, not Paragraph IV litigation.
• It did not decide patent validity, infringement, Orange Book listing status, biosimilar issues, or licensing rights.
• PTA audits should review prosecution events day by day.
• The ruling can affect generic-launch dates, Orange Book analysis, revenue forecasts, and patent valuation.
• The holding applies to U.S. patent-term adjustment and does not govern foreign patent-term systems.

Frequently Asked Questions

Does Gilead v. Lee apply to patent-term extension under 35 U.S.C. § 156?

No. The case concerns patent-term adjustment under 35 U.S.C. § 154(b). Patent-term extension under § 156 is a separate mechanism generally associated with regulatory review of drugs, biologics, and medical devices.

Can a patent owner still challenge a USPTO PTA calculation?

Yes. A patent owner may seek review under the statutory procedures applicable to PTA disputes. The challenge must address the USPTO’s calculation and the prosecution record supporting the claimed delay.

Does overlapping PTA reduce the patent’s original 20-year term?

No. The ruling does not shorten the baseline patent term. It limits the additional time added for overlapping USPTO delay.

Does the decision change FDA exclusivity periods?

No. FDA approval exclusivity and patent-term adjustment are separate legal regimes. The decision may change the patent expiration date used in commercial planning, but it does not alter NCE, orphan-drug, pediatric, or biologic exclusivity periods.

Is a formulation patent automatically entitled to PTA?

No. A formulation patent may qualify for PTA if the statutory requirements are met, but the amount depends on the prosecution record, agency delays, applicant delays, and overlapping periods.

References

Gilead Sciences, Inc. v. Lee, 778 F.3d 1341 (Fed. Cir. 2015).

U.S. Patent and Trademark Office. (2024). Manual of Patent Examining Procedure § 2730, patent term adjustment.

35 U.S.C. § 154(b) (2024).

35 U.S.C. § 156 (2024).

21 C.F.R. pt. 314 (2024).